Early clinical experience with imatinib in COVID-19: Searching for a dual effect-Reference-Cited by-同舟云学术

Early clinical experience with imatinib in COVID-19: Searching for a dual effect

Published:2021-05 Issue:5 Volume:82 Page:186-230
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Morales-Ortega Alejandro,Rivas-Prado Luis,Frutos-Pérez Begoña,Jaenes-Barrios Beatriz,Farfán-Sedano Ana Isabel,García-Parra Carlos Javier,Hernández-Muniesa Belén,Duarte-Millán Miguel Ángel,Madroñal-Cerezo Elena,Ontañón-Nasarre Ana,Ruiz-Giardín José Manuel,Bermejo Fernando,García-Gil Mario,Gonzalo-Pascua Sonia,San Martín-López Juan Víctor,Bernal-Bello David

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference10 articles.

1. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients;Chen;J Infect,2020

2. Sofosbuvir/daclatasvir in the treatment of COVID-19: a meta-analysis;Chan;J Infect,2020

3. Immunomodulation in COVID-19;Ingraham;Lancet Respir Med,2020

4. Imatinib for COVID-19: a case report;Morales-Ortega;Clin Immunol,2020

5. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey;Breccia;Leukemia,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2;International Journal of Molecular Sciences;2023-02-02

2. Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial;Journal of Medical Virology;2023-01-19

3. Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence;Immunity, Inflammation and Disease;2022-05-11

4. In silico and in vitro evaluation of imatinib as an inhibitor for SARS-CoV-2;Journal of Biomolecular Structure and Dynamics;2022-02-26

5. Imatinib in COVID-19: hope and caution;The Lancet Respiratory Medicine;2021-09